Rhythm Pharmaceuticals has announced that IMCIVREE (setmelanotide) has been granted marketing authorisation in Great Britain for treatment of obesity and control of hunger in Bardet-Biedl Syndrome.
Firstly this is great news! After the last post I made, I thought it would take months, maybe even years before a drug like this would be given authorisation in the UK, considering how strict someone of their health guidelines can be.
As we know already, Rhythm Pharmaceuticals, Inc. has dedicated years of work to transform the lives of patients living with hyperphagia and severe obesity caused by melanocortin-4 receptor (MC4R) pathway.
“The company has officially announced that Great Britain’s Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients 6 years of age and older.”
I’m not going to quote the whole article for copyright reasons and what-not. But definitely give it a read if you’re as excited as I am. This is massive news for all UK MC4r patients.
When I was first diagnosed, I would look up MC4r everyday looking for news like this. Everyday I found and read the same articles, with the same failed studies, and believed this day would never come.
But here it is – finally.
There really isn’t a lot for me to say this week. I know his medication is only being considered for patients with Bardet-Biedl Syndrome, but it’s a step in the right direction. That step, should give us all hope. Hope for a future where people with MC4r can be treated and hope for a future where our children may not have to go through what we went through.
But for the moment we wait, and we be happy for our fellow MC4r comrades with Bardet-Biedl Syndrome who are the first in line to be treated.
MC4r and ME 